Kynexis

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Monument Therapeutics

This biotech company develops digital biomarkers and targeted drugs to treat patients with schizophrenia and other neurological conditions.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.

Allyx

This clinical-stage biotechnology company develops oral small molecule therapies to protect synapses in patients with Alzheimer's disease and other neurodegenerative conditions.

Tortugas Neuroscience

The company develops small-molecule oral therapies for neurological and neuropsychiatric conditions, including schizophrenia, tinnitus and epilepsy, for patients with brain disorders.

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.

Axonis

This biotechnology company develops oral small molecule therapies targeting the KCC2 protein to treat patients with epilepsy, chronic pain and spinal cord injuries.